NCT02458313View on ClinicalTrials.gov

Nicotinic Agonist Effects on BMI and Neuronal Response

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Obesity
Interventions
DRUG

DMXB-A

150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.

OTHER

Placebo

Placebo capsules b.i.d. for 12 weeks

Trial Locations (1)

80045

University of Colorado, Denver

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02458313 - Nicotinic Agonist Effects on BMI and Neuronal Response | Biotech Hunter | Biotech Hunter